Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/42—Halides thereof
  • C07F9/425—Acid or estermonohalides thereof, e.g. RP(=X)(YR)(Hal) (X, Y = O, S; R = H, or hydrocarbon group)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
  • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
  • C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/40—Esters thereof
  • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
  • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
  • C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/40—Esters thereof
  • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
  • C07F9/4015—Esters of acyclic unsaturated acids

Definitions

• the present invention relates to new phosphorus-containing compounds which inhibit the activity of squalene synthetase and thus are useful in inhibiting cholesterol biosynthesis, to hypocholesterolemic compositions containing such compounds, to such compounds for use in a method for inhibiting cholesterol biosynthesis, to new intermediates formed in the preparation of such compounds and to a method for preparing such compounds.
• lower alkyl or “alkyl” as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 12 carbons in the normal chain, preferably 1 to 7 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethyl­pentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including a halo-substituent, such as F, Br, Cl or I or CF3, an alkoxy substituent, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloal
• cycloalkyl as employed herein alone or as part of another group includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substi­tuted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups, 1 or 2 hydroxy groups, 1 or 2 alkylamino groups, 1 or 2 alkanoyl­amino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups, and/or 1 or 2 alkyl­thio groups.
• aryl or “Ar” as employed herein refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl, substituted phenyl or substituted naphthyl wherein the substituent on either the phenyl or naphthyl may be 1, 2 or 3 lower alkyl groups, halogens (Cl, Br or F), 1, 2 or 3 lower alkoxy groups, 1, 2 or 3 hydroxy groups, 1, 2 or 3 phenyl groups, 1, 2 or 3 alkanoyloxy group, 1, 2 or 3 benzoyloxy groups, 1, 2 or 3 haloalkyl groups, 1, 2 or 3 halophenyl groups, 1, 2 or 3 allyl groups, 1, 2 or 3 cyclo­alkylalkyl groups, 1, 2 or 3 adamantylalkyl groups, 1, 2 or 3 alkylamino groups, 1, 2 or 3 alkanoyl­amino groups, 1, 2 or 3
• aralkyl refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.
• lower alkoxy as employed herein alone or as part of another group includes any of the above lower alkyl, alkyl, aralkyl or aryl groups linked to an oxygen atom.
• lower alkylthio as employed herein alone or as part of another group includes any of the above lower alkyl, alkyl, aralkyl or aryl groups linked to a sulfur atom.
• lower alkylamino as employed herein alone or as part of another group includes any of the above lower alkyl, alkyl, aryl or arylalkyl groups linked to a nitrogen atom.
• alkanoyl as used herein as part of another group refers to lower alkyl linked to a carbonyl group.
• halogen or "halo” as used herein refers to chlorine, bromine, fluorine, iodine and CF3, with chlorine or fluorine being preferred.
• metal ion refers to alkali metal ions such as sodium, potassium or lithium and alkali earth metal ions such as magnesium.
• Preferred are those compounds of formula I which have the following structure wherein Q is Z is -CH2CH2- or -CH CH-; R2 and R3 are each H or each F; R, R1 and R 1a are OH or metal ions.
• the compounds of formula I of the invention may be prepared according to the following reaction sequence and description thereof.
• compounds of Formula I may be prepared by treating monoacid II (wherein R4 is an alkyl group) in an aromatic solvent such as benzene or toluene, preferably containing dimethylformamide, or other appropriate inert organic solvent, with oxalyl chloride, and then evaporating the reaction mixture to give acid chloride III
• a lithium source such as n-butyl lithium or lithium diisopropylamide in a hexane or other inert organic solvent under an inert atmosphere such as argon to form the lithium salt IIIA
• the lithium salt IIIA is maintained at a reduced temperature as described above and acid chloride III in an inert organic solvent such as tetrahydrofuran or ethyl ether is added to form the phosphinyl-phosphonate IF.
• the lithium salt IIIA will be employed in a molar ratio to acid chloride III of within the range of from about 1.8:1 to about 2.5:1 and preferably from about 2.0:1 to about 2.4:1.
• Ester IF in an inert organic solvent such as methylene chloride, may then be subjected to dealkylation by treating with bromotrimethylsilane or iodotrimethylsilane in the presence of 2,4,6-collidine or bis(tri­methyl)silyltrifluoroacetamide and then treating with a strong inorganic base such as aqueous NaOH, KOH, LiOH or Mg(OH)2, optionally in the presence of an alcohol such as methyl alcohol, to form the salt IG which may be separated out by chromatography.
• Salt IG may be treated with a strong acid such as HCl to form acid IH.
• the starting materials II may be prepared as follows.
• starting material II may be prepared by treating halide V V X-Q-Z-Hal with trialkyl phosphite VI VI P(Oalkyl)3 under an inert atmosphere, such as argon, at an elevated temperature of within the range of from about 120 to about 165°C for a period of from about 1 to about 30 hours to form the phosphonic ester compound VII
• reaction of phosphite VI and halide V is carried out employing a molar ratio of VI:V of within the range of from about 2:1 to about 50:1.
• Phosphonic ester VII is subjected to basic hydrolysis such as by treatment with alkali metal hydroxide such as aqueous KOH or NaOH, optionally in the presence of an alcohol such as methanol, ethanol or isopropanol under an inert atmosphere, such as argon, at reflux temperature to form the phosphonic acid II which is a novel compound and thus forms a part of the present invention.
• alkali metal hydroxide such as aqueous KOH or NaOH
• an alcohol such as methanol, ethanol or isopropanol
• an inert atmosphere such as argon
• the starting halides V are either known or are prepared from farnesol or geraniol by conventional means.
• II may be prepared by treating halide VA or VB with the salt IIIB such as in the presence of an inert organic solvent such as tetrahydrofuran or ethyl ether at a reduced temperature of within the range of from about -78° to about 0°C for a period within the range of from about 1 to about 24 hours, to form the phosphonic ester VIIA which is subjected to basic hydrolysis as described above for scheme B(1) to form phosphinic acid starting material II.
• an inert organic solvent such as tetrahydrofuran or ethyl ether
• the reaction of VA or VB and IIIB is carried out employing a molar ratio of VA or VB:IIIB of about 1:1.
• the salt IIIB is formed by treating phosphonate IIIB′ in an inert organic solvent such as tetrahydrofuran or ethyl ether under an inert atmosphere such as argon with a source of alkali metal such as n-butyllithium in an inert organic solvent such as hexane.
• an inert organic solvent such as tetrahydrofuran or ethyl ether under an inert atmosphere such as argon
• a source of alkali metal such as n-butyllithium in an inert organic solvent such as hexane.
• the starting halides VA or VB are either known or prepared from geraniol or farnesol by conventional means.
• phosphonic ester X a novel compound in accordance with the present invention
• reaction of aldehyde VIII and phosphonate IX is carried out employing a molar ratio of VIII:IX of within the range of from about 1:1 to about 1:2.
• the aldehyde starting material VIII where Q is a bond and p is 0, that is geranial, is a known compound.
• Q is and p is 0 is farnesal, a known compound.
• starting aldehydes and starting alcohols are either known in the art or prepared from geraniol or farnesol employing conventional chemical synthesis.
• novel intermediates in accordance with the invention may be defined by the following formula: wherein R5 is OH or Cl.
• the compounds of the present invention are inhibitors of squalene synthetase and thus are useful in inhibiting cholesterol biosynthesis and treating hypercholesterolemia and atherosclerosis. Inhibition of squalene synthetase may be measured by the following procedure.
• Rat liver microsomal squalene synthetase activity is measured using farnesyl pyrophosphate as substrate and quantitating squalene synthesis using gas chromatographic analysis.
• the assay was developed by modifying conditions originally described by Agnew (Methods in Enzymology 110:357, 1985).
• Livers are dissected from 2 or 3 decapitated Sprague Dawley rats and are quickly transferred to ice cold buffer (potassium phosphate, 0.05 M, (pH 7.4); MgCl2, 0.004 M; EDTA, 0.001 M; and 2-mercaptoethanol 0.01 M) and rinsed thoroughly.
• the livers are minced in cold buffer (2.0 ml/g) and homogenized using a Potter-Elvejhem homogenizer. The homogenate is centrifuged at 5,000 x g, 10 minutes (4°C), and the supernatant poured through 2 layers of cheese cloth. The supernatant is then centrifuged at 15,000 x g for 15 minutes (4°).
• the supernatant is filtered through 2 layers of cheese cloth, and centrifuged a third time at 100,000 x g for 1.0 hour at 4°C. Following centrifugation the microsomal pellet is resuspended in a volume of buffer equivalent to 1/5 the volume of the original homogenate; and homogenized in a ground glass homogenizer. Aliquotted microsomes are frozen at -80°C, and retain activity for at least two months.
• Reaction Mixtures are prepared in 50 ml round bottom pyrex glass tubes with tight-fitting, teflon-lined, screw caps. Tubes are cooled to 4°C, and the following components are added in sequence: 1. Potassium phosphate buffer 0.275 M, pH 7.4) 0.36 ml 2. KF (55 mM) 0.36 ml 3. NADPH (5.0 mM, freshly prepared) 0.36 ml 4. H2O (or H2O + test compound) 0.16 ml 5. MgCl2 (27.5 mM) 0.36 ml 6. Microsomal Enzyme (0.48 mg microsomal protein in homogenization buffer) (15 ⁇ l prep. 4/23/86) 0.20 ml 1.8 ml
• the upper organic phase fractions are pooled in glass 20.0 ml scintillation vials and reduced in volume to ⁇ 1.0 ml under a stream of N2.
• the sample is then transferred to acid-washed, conical bottom, glass (1.0 ml) microvials, and brought to dryness under N2.
• the residue is resuspended in 50 ⁇ l hexane (spectral grade), and these samples are spun at 1000 rpm at room temperature for 10 minutes. Following centrifugation approximately 40 ⁇ l of supernatant is transferred to 100 ⁇ l acid-washed microvials with septa/crimp-top caps (compatible with the Hewlett-Packard GC auto injector).
• the injector temperature is 200°C, and the FID detector temperature is set at 270°C.
• Oven temperature is programmed through a two ramp sequence as follows:
• docosane (internal standard) has a retention time of 3.6-3.7 minutes, and squalene has a retention time of 14.7-14.9 minutes.
• the amount of squalene in each reaction mixture is determined by obtaining the areas under the squalene and docosane peaks and using the following formula to calculate the amount of squalene (nmoles) in the total reaction mixture.
• a further aspect of the present invention is a pharmaceutical composition consisting of at least one of the compounds of Formula I in association with a pharmaceutical vehicle or diluent.
• the pharmaceutical compostion can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration.
• the compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations.
• the dose for adults is preferably between 200 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.
• a typical capsule for oral administration contains active ingredient (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
• a typical injectible preparation is produced by asceptically placing 250 mg of sterile active ingredient into a vial, asceptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 ml of physiological saline, to produce an injectible preparation.
• Example 2 To a stirred solution of 1.02 g (3.23 mmol) of Example 1, Part C mono-acid in 15 ml of benzene was added 0.85 ml (9.69 mmol) of oxalyl chloride over five minutes with much gas evolution. After 40 minutes, a drop of DMF was added, resulting in additional gas evolution, followed one hour later with another drop of DMF, resulting in no gas evolution. The solvent was evaporated, and the residue was twice redissolved in benzene and re-evaporated, and then placed under high vacuum until use.
• the reaction was allowed to stir at -78°C for two hours, and was stored at -85°C in a freezer for 16 hours.
• the reaction was quenched with 0.2 ml (3.50 mmol) of acetic acid in 4 ml of ether, followed by dilution with ether and acidification with 10% HCl.
• the ether layer was washed with water and brine, dried and evaporated to give 1.56 g of a yellow liquid.
• the dark orange liquid was pumped at high vacuum, and was treated with a solution of 1 ml (7.0 mmol) of triethylamine in 9 ml of methanol, yielding a colorless solution. After 15 minutes, the methanol was evaporated and the residue was dissolved in 4 ml of water and basified with 4.7 ml of 1 M KOH. The solution was reduced in volume to about 4 ml and the mixture was flash chromatographed on HP-20 eluted with a water acetonitrile gradient to give 574 mg of impure material.
• the crude product was partially purified by flash chromatography on silica gel, eluted with 50:50 ethyl acetate:hexane, and the crossover fractions were rechromatographed eluting with 25:75 followed by 75:25 ethyl acetate:hexane. This procedure provided 0.946 g (13%) of the 1E,3Z-isomer and 5.29 g (72%) of the desired title 1E,3E-isomer.
• the pale yellow solution was allowed to stir for 30 minutes at -78°C and the above-described chloride was added in 4 ml of THF over 10 minutes.
• the dark solution was maintained at -78°C for 1.5 hours and then placed in a -85°C freezer for 15 hours.
• the reaction was quenched with 0.3 ml of acetic acid in 4 ml of ether and allowed to warm to room temperature.
• the mixture was partitioned between ether and 10% HCl, and the ether layer was washed with water and saturated NaHCO3.
• the combined aqueous layers were extracted with two portions of dichloromethane, and the combined organic layers were dried (MgSO4) and evaporated to provide 1.62 g of an orange oil.
• HMPA hexamethyl phosphoric triamide

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22497032

Family Applications (1)

Country Status (8)

Cited By (23)

Families Citing this family (115)

• 1988
  • 1988-01-11 US US07/141,744 patent/US4871721A/en not_active Expired - Fee Related
  • 1988-12-13 NZ NZ227303A patent/NZ227303A/en unknown
• 1989
  • 1989-01-04 ZA ZA8953A patent/ZA8953B/xx unknown
  • 1989-01-09 AU AU28321/89A patent/AU615507B2/en not_active Ceased
  • 1989-01-10 EP EP89100309A patent/EP0324421A3/de not_active Ceased
  • 1989-01-10 HU HU8977A patent/HU203894B/hu not_active IP Right Cessation
  • 1989-01-10 DK DK008889A patent/DK8889A/da not_active Application Discontinuation
  • 1989-01-11 JP JP1005869A patent/JPH01213288A/ja active Pending

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events